Latest / EMJ Podcast: Insights For Healthcare Professionals
Atypical EGFR Mutations in the Community Clinic: Testing, Treatment, and Emerging Evidence
This content was funded by Johnson & Johnson. This material is intended for educational and scientific exchange purposes only. It is not intended to be promotional and should not be used to make treatment decisions for any individual patient. The views expressed are those of the speaker and do not necessarily reflect those of Johnson & Johnson.
Atypical EGFR mutations make up approximately 5 to 10% of EGFR-mutant NSCLC, and because some assays only report exon 19 deletions and L858R, they are easy to miss. In this short podcast, Melina Marmarelis, thoracic oncologist at the University of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.